Reduced exposure to calcineurin inhibitors in renal transplantation.
By Markus Guba, Karl-Walter Jauch. New England Journal of Medicine, 2008
1,433 citations recorded by the source corpus.
Subfields: Pediatrics, Perinatology and Child Health, Surgery, Transplantation
View Paper: https://www.semanticscholar.org/paper/f3ccd5875810470ce9b0261172535eaef0e7a9e6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Surgery
In Transplantation
Citations in the corpus
- The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody‐mediated rejection, and prospects for integrative endpoints for next‐generation clinical trials (2018, background): “” American Journal of Transplantation 18 (2): 293-307.”
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing (2015, background): “mus with target concentrations of 3–7 ng/mL had less rejection and better kidney function.(10) Although TDM is helpful for adjusting subsequent doses based on blood concentrations, it provides no”
- A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study) (2010, background): “The 13–15 mL/min glomerular filtration rate renal function improvement in patients who received belatacept compared with cyclosporine is generally better than the 4–5 mL/min improvement observed with sirolimus- or tacrolimus-based immunosuppression regimens in kidney transplant recipients (35,36).”
- KDIGO clinical practice guideline for the care of kidney transplant recipients. (2009, neutral): “Hct, % Beckingham 1995,108 England, UK 4 mo 15 (15) 10 (10) Enalapril 2.”